Overview

Study of Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients

Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of selinexor and HAAG +/- HMA in relapsed/refractory acute leukemia (AML) patients.
Phase:
N/A
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University
Treatments:
Aclacinomycins
Azacitidine
Cytarabine
Decitabine
Homoharringtonine
Lenograstim